Potent and selective inhibitor of phospholipase D2 (PLD2) in cellular (PLD1 IC50 = 1900nM Calu-1 cells; PLD2 IC50 = 90nM HEK293-gfpPLD2 cells) and in vitro (hPLD1 IC50 = >20’000nM; hPLD2 IC50 = 500nM) assays.
Product Details
| Alternative Name: | N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)-ethyl)quinoline-3-carboxamide, VU0285655-1 |
| |
| Formula: | C25H27N5O2 |
| |
| MW: | 429.5 |
| |
| CAS: | 1158347-73-9 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO (>25mg/ml) or 100% ethanol (>25mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity: R. Lavieri, et al.; Bioorg. Med. Chem. Lett.
19, 2240 (2009),
Abstract;
